世界の狭心症治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

【英語タイトル】Global Angina Pectoris Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが出版した調査資料(MOR22FB099)・商品コード:MOR22FB099
・発行会社(調査会社):Mordor Intelligence
・発行日:2022年1月
・ページ数:120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,750 ⇒換算¥703,000見積依頼/購入/質問フォーム
Team User(5名利用)USD6,500 ⇒換算¥962,000見積依頼/購入/質問フォーム
Corporate License(法人利用)USD8,750 ⇒換算¥1,295,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Mordor Intelligence社の本調査レポートでは、世界の狭心症治療薬の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療クラス別(ベータ遮断薬、カルシウムチャネル遮断薬、硝酸塩、アンジオテンシン変換酵素阻害剤(ACE阻害剤)、抗血小板)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の狭心症治療薬市場規模:治療クラス別(ベータ遮断薬、カルシウムチャネル遮断薬、硝酸塩、アンジオテンシン変換酵素阻害剤(ACE阻害剤)、抗血小板)
・世界の狭心症治療薬市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Amgen、Bayer AG、Eli Lilly and Company、Gilead Sciences、GlaxoSmithKline Plc.、Merck & Co., Inc.、Novartis AG、Otsuka Pharmaceutical Co. Ltd、Pfizer Inc.、Sanofi)
・市場機会・将来傾向

Lifestyle diseases and their chronic nature is among the pivotal reason for the high cardiovascular-related disorders globally. As per the Nesia Foundation Hospital, globally, about 14.2 million people between the age group 30-69 years, die prematurely from lifestyle disorders such as diabetes, arteriosclerosis, high cholesterol, stroke, nephritis, cancer, and several others. As per several published data on lifestyle-related diseases, women have more atypical signs of heart attack more often than men. In addition, in several cases, there is increased misdiagnosis or delayed diagnosis which eliminate the likeliness to receive immediate life-saving treatment of primary angioplasty and stents. The increasing burden of lifestyle diseases directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment. Thus, increasing burden of lifestyle diseases majorly drives the demand and need for angina pectoris drugs market.

Key Market Trends

Beta Blockers is Expected to Hold Smallest Share of Global Angina Pectoris Drugs Market, Over the forecast period

Beta blockers work by blocking the effect of adrenaline on the heart by providing benefits such as Slowing of the heart rate and reducing the force of heart muscle contraction. In patients with stable angina caused by CAD, beta blockers are considered first-line therapy. Beta Blockers has the smallest share in the market as the majority of beta-blocker drugs are predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.

North America Region Holds the Largest Market Share of Angina Pectoris Drugs Market

North America dominates the Angina Pectoris Drugs market due to the established healthcare infrastructure, increased adoption of therapeutics and presence of key manufacturers in the U.S are responsible for its large share. Ischaemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.

Competitive Landscape

Some of the prominent industry players operating in total Angina Pectoris Drugs market include Amgen, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc and Merck & Co., Inc. Development of advanced products for better outcomes and rigorous marketing are some of the competitive strategies adopted by market players.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
❖ レポートの目次 ❖

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Lifestyles Diseases
4.2.2 Technological Advancements towards Personalized Cardiovascular Medicines
4.2.3 Augmentation of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Adoption of Minimally Invasive Surgeries
4.3.2 Side Effects Associated with Certain Drug Classes
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapeutic Class

5.1.1 Beta Blockers
5.1.2 Calcium Channel Blockers
5.1.3 Nitrates
5.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
5.1.5 Anti-Platelets
5.1.6 Others
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline Plc.
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 Otsuka Pharmaceutical Co. Ltd
6.1.9 Pfizer Inc.
6.1.10 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



★調査レポート[世界の狭心症治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測] (コード:MOR22FB099)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の狭心症治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆